The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States

Neuro-Oncology

Volumn 15, Issue 11, 2013, Pages 1532-1542

  Messali, Andrew ^a   Hay, Joel W ^a   Villacorta, Reginald ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Brain tumor; Cost effectiveness; Glioblastoma; Health technology assessment; Temozolomide

Indexed keywords

TEMOZOLOMIDE;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; GLIOBLASTOMA; HEALTH CARE COST; HUMAN; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; UNITED STATES;

BRAIN TUMOR; COST-EFFECTIVENESS; GLIOBLASTOMA; HEALTH-TECHNOLOGY ASSESSMENT; TEMOZOLOMIDE;

ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; DACARBAZINE; GLIOBLASTOMA; HUMANS; MARKOV CHAINS; TIME FACTORS; UNITED STATES;

EID: 84891867206     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not096     Document Type: Article

References (40)

1. Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006;2(9): 494-503. quiz 491 p following 516
2. Central Brain Tumor Registry of the United States. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2007. Hinsdale, IL: 2011.http://www.cbtrus.org/2011-NPCR-SEER/ WEB-0407-Report-3-3- 2011.pdf. Accessed 27 May 2013
3. Chamberlain MC, Kormanik PA. Practical guidelines for the treatment of malignant gliomas. West J Med. 1998;168(2):114-120
4. WalkerMD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49(3):333-343
5. Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer. 1981;47(4):649-652
6. Stupp R, Hegi ME, MasonWP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466
7. Stewart LA. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359(9311):1011-1018
8. Green SB, Byar DP, Walker MD, et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep. 1983;67(2):121-132
9. Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management ofmalignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer. 1983;52(6):997-1007
10. Shapiro WR, Green SB, Burger PC, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg. 1989;71(1):1-9
11. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical ResearchCouncil trial. J Clin Oncol. 2001;19(2):509-518
12. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996
13. Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res. 2005;11(19 Pt 1):6767-6771
14. Athanassiou H, SynodinouM,Maragoudakis E, et al.Randomized phase 2 study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol. 2005;23(10):2372-2377
15. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the 'DEALE'). I. Validation of the method. Am J Med. 1982; 73(6):883-888
16. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the 'DEALE'). 2. Use in medical decision-making. Am J Med. 1982;73(6):889-897
17. Silverstein MD, Cascino TL, Harmsen WS. High-grade astrocytomas: resource use, clinical outcomes, and cost of care. Mayo Clin Proc. 1996;71(10):936-944
18. Department of Veterans Affairs. Drug pharmaceutical prices. http:// www.pbm.va.gov/drugpharmaceuticalprices.asp (accessedMay 27, 2013)
19. Assistant Secretary for Planning and Evaluation DoHaHS. Expanding the Use of Generic Drugs. 2010
20. Hayman JA, Langa KM, Kabeto MU, et al. Estimating the cost of informal caregiving for elderly patients with cancer. J Clin Oncol. Jul 1 2001;19(13): 3219-3225
21. Bureau of Labor Statistics DoOES. The National Compensation Survey. 2012; http://www.bls.gov/oes/current/oes311011.htm, 2013
22. Garside R, Pitt M, Anderson R, et al. The effectiveness and costeffectiveness of carmustine implants and temozolomide for the treatmentof newly diagnosed high- grade glioma: A systematic reviewand economicevaluation. Health Technol Assess. 2007;11(45):3-4, 9-221
23. Drummond MF, Bloom BS, Carrin G, et al. Issues in the cross-national assessment of health technology. Int J Technol Assess Health Care. 1992;8(4):671-682
24. Greiner W, Schoffski O. The transferability of international economic health- economic results to national study questions. Health Econ Prev Care. 2000;1(2):94-102
25. Lamers LM, Stupp R, van den Bent MJ, et al. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: A report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. Cancer. 2008;112(6):1337-1344
26. Gold MRSJ, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. Oxford: Oxford University Press; 1996
27. Wu B, Miao Y, Bai Y, et al. Subgroup economic analysis for glioblastoma in a health resource-limited setting. PLoS ONE. 2012;7(4):e34588
28. Chung KC, Oda T, Saddawi-Konefka D, Shauver MJ. An economic analysis of hand transplantation in the United States. Plast Reconstr Surg. 2010;125(2):589-598
29. Novak EJ, Silverstein MD, Bozic KJ. The cost-effectiveness of computerassisted navigation in total knee arthroplasty. J Bone Joint Surg Am. 2007;89(11):2389-2397
30. Brauer CA, Rosen AB, Olchanski NV, Neumann PJ. Cost-utility analyses in orthopaedic surgery. J Bone Joint Surg Am. 2005;87(6):1253-1259
31. Neumann PJ, Sandberg EA, Bell CM, Stone PW, Chapman RH. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood). 2000;19(2):92-109
32. Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA. 2000;283(7):889-896
33. Newby LK, Eisenstein EL, Califf RM, et al. Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med. 2000;342(11):749-755
34. Ubel PA, HirthRA,ChernewME,FendrickAM.Whatis the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163(14):1637-1641
35. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992; 146(4):473-481
36. Braithwaite RS, Meltzer DO, King JT, Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46(4): 349-356
37. Lee CP, Chertow GM, Zenios SA. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health. 2009;12(1):80-87
38. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3):332- 342
39. World Health Organization. Macroeconomics and Health: Investing in Health for Economic Development. Geneva, Switzerland: Author; 2001
40. Taphoorn MJ, Stupp R, Coens C, et al. Health-related quality of life in patients with glioblastoma: A randomised controlled trial. Lancet Oncol. 2005;6(12):937-944